Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Delonix Bio Raises $14 Million in Seed Financing for Synthetic Vaccines

publication date: Mar 12, 2021

Shanghai Delonix Bioworks, a startup biotech developing synthetic biology vaccines, closed a $14 million seed financing. Delonix's synthetic biology and antigen discovery platforms are designed to offer rational design and programming of bacteria to create vaccines with better safety and efficacy. Its current lead programs target anti-microbial resistance. The seed round was led by Boehringer Ingelheim Venture Fund and IDG Capital. ZhenFund and an undisclosed investor also participated. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital